Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises funds managed by Stirling Square Capital Partners
Mandate

Vinge advises funds managed by Stirling Square Capital Partners

August 25, 2010

Vinge has advised funds managed by Stirling Square Capital Partners in relation to the Swedish aspects of the purchase of Environmental Solutions Europe Holding B.V. (“ESEH”) from OTTO Group.

ESEH is a market leader within the waste management industry providing environmentally-related products and services including the design and development of waste management containers and recycling systems. ESEH has 900 employees and currently conducts operations in 20 countries. Stirling Square intends to expand ESEH’s geographical reach by launching new products and services.

Vinge’s team consisted of, among others, partners Christina Kokko and Maria-Pia Midenbäck-Hope and associates Sarah Khalil and Paul Dali.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024